File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy

TitleThe experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy
Authors
Issue Date2007
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast
Citation
10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 n. Suppl 1, p. S51, abstract no. P134 How to Cite?
AbstractObjective: Sentinel lymph node biopsy (SLNB) is well accepted as part of management of early breast cancer. As neo-adjuvant chemotherapy (NACT) is increasingly used in management of locally advanced breast cancer (LABC), breast conservative surgery has become a possibility even for patients who initially present with large tumours. However reports on the performance of sentinel lymph node biopsy (SLNB) following neo-adjuvant chemotherapy (NACT) have been conflicting. In addition, limited number of reports from Chinese breast cancer patients are available. This study aims to evaluate the results of SLNB after neo-adjuvant chemotherapy in Chinese breast cancer patients. Methods: A retrospective study was performed for breast cancer patients who had SLNB after prior neo-adjuvant chemotherapy. Adriamycin-based or taxane-based chemotherapy was given as neo-adjuvant treatment. A combination of radiopharmaceutical 99mTc-albumin colloid and Patent Blue V dye was used to identify the sentinel lymph node (SLN). SLNB was followed by standard axillary dissection in all patients. Results: 365 patients received SLNB during the period of May 1999 to April 2006. A total of 78 patients with neo-adjuvant chemotherapy followed by SLNB were recruited. The SLN identification rate, false-negative rate and accuracy rate were 83.3%, 24.2% and 73.1% respectively. SLNs were identified in 11 (84.6%) of 13 patients with complete clinical response and no false-negative SLN was found. SLNs were found in 54 (83.1%) of 65 patients with partial or no clinical response and false-negative rate was 25%. In the 7 patients with complete pathological response, 6 (85.7%) had SLNs identified with no false-negative node. In the 71 patients with partial or no pathological response, 59 (83.1%) had SLN identified with a false-negative rate of 24.2%. Conclusion: The failed localization and false-negative rates of SLNB after neoadjuvant chemotherapy were unacceptably high in our cohort, concurrent with various published studies. Inaccuracy increases in patients with less than complete clinical or pathological tumor response.
Persistent Identifierhttp://hdl.handle.net/10722/182316
ISSN
2015 Impact Factor: 2.74
2015 SCImago Journal Rankings: 1.346
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwong, A-
dc.contributor.authorSuen, DTK-
dc.contributor.authorCheung, TT-
dc.date.accessioned2013-04-22T02:06:10Z-
dc.date.available2013-04-22T02:06:10Z-
dc.date.issued2007-
dc.identifier.citation10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 n. Suppl 1, p. S51, abstract no. P134-
dc.identifier.issn0960-9776-
dc.identifier.urihttp://hdl.handle.net/10722/182316-
dc.description.abstractObjective: Sentinel lymph node biopsy (SLNB) is well accepted as part of management of early breast cancer. As neo-adjuvant chemotherapy (NACT) is increasingly used in management of locally advanced breast cancer (LABC), breast conservative surgery has become a possibility even for patients who initially present with large tumours. However reports on the performance of sentinel lymph node biopsy (SLNB) following neo-adjuvant chemotherapy (NACT) have been conflicting. In addition, limited number of reports from Chinese breast cancer patients are available. This study aims to evaluate the results of SLNB after neo-adjuvant chemotherapy in Chinese breast cancer patients. Methods: A retrospective study was performed for breast cancer patients who had SLNB after prior neo-adjuvant chemotherapy. Adriamycin-based or taxane-based chemotherapy was given as neo-adjuvant treatment. A combination of radiopharmaceutical 99mTc-albumin colloid and Patent Blue V dye was used to identify the sentinel lymph node (SLN). SLNB was followed by standard axillary dissection in all patients. Results: 365 patients received SLNB during the period of May 1999 to April 2006. A total of 78 patients with neo-adjuvant chemotherapy followed by SLNB were recruited. The SLN identification rate, false-negative rate and accuracy rate were 83.3%, 24.2% and 73.1% respectively. SLNs were identified in 11 (84.6%) of 13 patients with complete clinical response and no false-negative SLN was found. SLNs were found in 54 (83.1%) of 65 patients with partial or no clinical response and false-negative rate was 25%. In the 7 patients with complete pathological response, 6 (85.7%) had SLNs identified with no false-negative node. In the 71 patients with partial or no pathological response, 59 (83.1%) had SLN identified with a false-negative rate of 24.2%. Conclusion: The failed localization and false-negative rates of SLNB after neoadjuvant chemotherapy were unacceptably high in our cohort, concurrent with various published studies. Inaccuracy increases in patients with less than complete clinical or pathological tumor response.-
dc.languageeng-
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast-
dc.relation.ispartofThe Breast-
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in The Breast. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Breast, [VOL 1, ISSUE S1, 2007]-
dc.titleThe experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapyen_US
dc.typeConference_Paperen_US
dc.identifier.emailKwong, A: avakwong@HKUCC.hku.hk-
dc.description.natureabstract-
dc.identifier.doi10.1016/S0960-9776(07)70194-7-
dc.identifier.hkuros136505-
dc.identifier.volume16-
dc.identifier.issueSuppl 1-
dc.identifier.spageS51 P134-
dc.identifier.epageS51 P134-
dc.identifier.isiWOS:000257274600164-
dc.publisher.placeUnited Kingdom-
dc.description.other10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 n. Suppl 1, p. S51 P134-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats